196 related articles for article (PubMed ID: 25721433)
1. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.
McCormack PL
Drugs; 2015 Apr; 75(5):515-24. PubMed ID: 25721433
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
3. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
Herbst DA; Reddy KR
Expert Opin Investig Drugs; 2013 Oct; 22(10):1337-46. PubMed ID: 23931586
[TBL] [Abstract][Full Text] [Related]
4. Daclatasvir for the treatment of chronic hepatitis C virus infection.
Temesgen Z; Rizza SA
Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
[TBL] [Abstract][Full Text] [Related]
5. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Smith MA; Regal RE; Mohammad RA
Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
[TBL] [Abstract][Full Text] [Related]
6. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
7. Daclatasvir for the treatment of chronic hepatitis C.
Degasperi E; Aghemo A; Colombo M
Expert Opin Pharmacother; 2015; 16(17):2679-88. PubMed ID: 26549010
[TBL] [Abstract][Full Text] [Related]
8. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir: potential role in hepatitis C.
Lee C
Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
[TBL] [Abstract][Full Text] [Related]
10. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hong CM; Liu CJ; Yeh SH; Chen PJ
J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
[TBL] [Abstract][Full Text] [Related]
13. Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.
Bonora S; Puoti M
AIDS Rev; 2017; 19(1):24-34. PubMed ID: 28182611
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
16. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of daclatasvir in hepatitis C virus.
Izumi N
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1025-31. PubMed ID: 25059552
[TBL] [Abstract][Full Text] [Related]
20. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
